
# RegEngine Audit & QA Report
**Date:** 2026-02-04
**Version:** 1.0

## Executive Summary
This report details the findings of the Phase 1 (Tenant Isolation) and Phase 2 (Data Integrity) audit cycles for the RegEngine platform.

| Phase | Test Suite | Status | Critical Findings |
|-------|------------|--------|-------------------|
| **Phase 1** | Tenant Isolation | ✅ PASSED | **0** cross-tenant leaks detected. RLS "Double-Lock" verified. |
| **Phase 2a** | Schema Invariants (Remote) | ✅ PASSED | **0** invalid records. (Note: DB was empty). |
| **Phase 2b** | Golden Corpus Ingestion | ⏳ PENDING | Pending Environment Setup. |

### Security Scan Status
| Tool | Target | Status |
|------|--------|--------|
| Snyk | Dependency Vulnerabilities | 🟡 Planned |
| OWASP ZAP | DAST / API Endpoint Scan | 🟡 Planned |

---

## Phase 1: Security & Tenant Isolation
**Objective:** Verify "Double-Lock" Row-Level Security (RLS) enforcement.

### Methodology
*   **Strategy:** Adversarial testing via direct DB connection.
*   **Mechanism:**
    1.  Connect as superuser (or elevated role).
    2.  Insert data for `Tenant A` and `Tenant B`.
    3.  Switch context to `Tenant A` (using `SET role` + `SET app.tenant_id`).
    4.  Attempt to query `Tenant B` data.
    5.  Attempt to query data with `NULL` tenant context.

### Results
*   **Test File:** `tests/security/test_tenant_isolation_phase1.py`
*   **Outcome:**
    *   `test_rls_enforcement_on_audit_logs`: **PASSED** (Tenant B data invisible to Tenant A)
    *   `test_public_access_denied`: **PASSED** (No data visible without Tenant ID)

**Conclusion:** The RLS architecture is correctly implemented and enforced at the database level.

---

## Phase 2: Data Integrity & FDA Compliance
**Objective:** Verify that the system correctly ingests, parses, and structures FSMA 204 data ("Golden Corpus").

### Phase 2a: Schema Invariants (Remote)
**Status:** ✅ PASSED (Vacuous)
*   **Finding:** The remote production database is currently empty of `pcos_authority_documents`.
*   **Implication:** No invalid data exists, but the "Golden Corpus" logic remains untested in the current environment.

### Regulatory Freshness Status
| Authority | Last Check | Latency Target | Status |
|-----------|------------|----------------|--------|
| FDA FSMA 204 | — | < 24h | 🔴 Not yet monitored |

### Phase 2b: Golden Corpus Verification (Next Steps)
**Objective:** End-to-end verification of the ingestion pipeline.
**Plan:**
1.  Boot full Docker stack (`scripts/start-stack.sh`).
2.  Ingest FDA FSMA 204 Final Rule (PDF).
3.  Verify extraction of Key Data Elements:
    *   Traceability Lot Code (TLC) Requirement
    *   2-Year Retention Period
    *   Critical Tracking Events (CTEs)

---

## Limitations & Exclusions
**Auditor Note:** This report covers security and data integrity verification.
1.  **Phase 2a (Data Invariants):** The remote production database (`pcos_authority_documents` table) was found to be empty at the time of audit ("Vacuous Truth"). While no invalid data exists, the schema's ability to enforce invariants on *actual* data is inferred but not empirically proven by the Phase 2a suite alone. **Phase 2b** is required to provide positive proof of correctness.
2.  **Scope:** This audit verifies the *platform's* enforcement engines (RLS, Ingestion Logic). It does not certify the legal validity of the content provided by external regulators (FDA).

### Scope Boundaries
- **Authorities Covered:** FDA FSMA 204 only (additional authorities planned)
- **Evidence Matching:** Not yet implemented (Phase 3)
- **LLM Components:** None in production (deterministic parsing only) - *Auditor Note: System relies on provable rule-based extraction, not probabilistic models.*
